We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune checkpoint inhibitor‐induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system.
- Authors
Moore, Donald C.; Elmes, Joseph B.; Arnall, Justin R.; Strassels, Scott A.; Patel, Jai N.
- Abstract
Three cases of ICI-induced AHA have been described in the literature (Table 2).7-9 The time to onset of ICI-induced AHA ranged from 6 weeks to 17 months. Since, their entry into oncologic therapy, immune checkpoint inhibitors (ICIs) have made a profound impact on treatment paradigms and outcomes associated with a variety of malignancies. AHA secondary to ICI therapy may lead to permanent discontinuation of ICI therapy, which can potentially impact outcomes for patients with cancer receiving these therapies.
- Subjects
UNITED States. Food &; Drug Administration; IMMUNE checkpoint proteins; BRUISES; DRUG side effects; HEMOPHILIA; MEDICAL personnel; GASTROINTESTINAL hemorrhage; IMMUNE checkpoint inhibitors
- Publication
Haemophilia, 2022, Vol 28, Issue 5, pe145
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14632